Skip to main content

Table 1 Comparison of clinical features between LUAD patients with low and high Kremen2 levels in TCGA database

From: Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR

Clinical character

Clinical groups

Kremen2 protein expression

P-value

Low(n = 248)

High(250a)

T stage

T1

90

75

0.041*

T2

135

132

T3

14

31

T4

9

9

Pathological Grade

Stage I

144

128

0.045*

Stage II

62

57

Stage III

32

51

Stage IV

10

14

  1. *P < 0.05
  2. aAmong them, three samples have no T stage information but have pathological grade information
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us